New Drugs of 2013, Part 1

Michael A. Mancano, PharmD
Published Online: Friday, January 17, 2014

New Drugs of 2013, Part 1

Michael A. Mancano, PharmD
Clinical Professor of Pharmacy Practice
Chair, Department of Pharmacy Practice
Temple University School of Pharmacy
Clinical Consultant Pennsylvania Hospital
Department of Pharmacy
Philadelphia, Pennsylvania

The following contributors have no relevant financial relationships with commercial interests to disclose.

Michael A. Mancano, PharmD

Pharmacy Times Office of Continuing Professional Education
Planning Staff—David Heckard; Maryjo Dixon, RPh; and Steve Lin, PharmD, RPh

Pharmacy Times
Editorial Staff—Kirk McKay

Upon completing this continuing education program, participants should be able to:
1. Discuss the clinical indications of the new drugs approved by the FDA in 2013.
2. Explain the various mechanisms of action of the drugs discussed within this program.
3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
4. Identify the most common adverse reactions of the new drugs approved in 2013.
5. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Target audience: Pharmacists
Type of activity: Knowledge
Release date: January 12, 2014
Expiration date: January 12, 2016
Estimated time to complete activity: 2 hours
Fee: Free

Click here to view this activity.

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. TDescription: Description: Description: Pharmacy Times/Ascend Media Office of Continuing Professional Educationhis activity is approved for 2 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-14-002-H04-P. The activity is available for CE credit through January 12, 2016.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues